NITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Serial No.:

Continuation of 09/079,569

Group Art Unit No.:

Filed:

December 14, 1998

Examiner: Not Assigned

For:

Antibodies Specific for Osteoprotegerin Binding Proteins

and Method of Use

Docket No.:

A-451H

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Under the guidelines of 37 C.F.R. 1.97, applicant submits a copy of each of the references listed on the attached supplemental PTO-1449 (Modified) form for consideration by the Examiner.

Applicant, by the undersigned attorney/agent, certifies that each item contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Applicant requests consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen, Inc. An original and one copy of this paper are enclosed.

Respectfully submitted,

Robert B. Winter

Attorney/Agent for Applicant(s) Registration No.: 34,458

Phone: (805) 447-2425

Date:

Please send all future correspondence to:

U.S. Patent Operations/RBW Dept. 430, M/S 27-4-A AMGEN INC. One Amgen Center Drive Thousand Oaks, California 91320-1789 RECEIVED

DEC 62 1000

LAVICE CENTER

EXPRESS MAIL CERTIFICATE

"Express Mail" mail labeling number: EL198793066US Date of Deposit: December 14, 1998

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Soreyben